Genmab — Juli 2018
-
God morgen
-
article on daratumumab interference with standard types of blood-compatibility tests - F(ab′)2 Fragments to Overcome Daratumumab Interference in Transfusion Tests - https://www.nejm.org/doi/full/10.1056/NEJMc1804751
-
So Dara now has EMA orphan designation for Treatment of AL amyloidosis http://www.ema.europa.eu/docs/en_GB/document_library/Minutes/2018/06/WC500251173.pdf p18 - http://www.ema.europa.eu/docs/en_GB/document_library/Committee_meeting_report/2018/06/WC500250581.pdf
p7 -
That is certanly good news. Thank you E L.
-
-
Det er en meget lille indikation uden effektive behandlingsmuligheder.
-
Jeg mener, at Novod for et par år siden fortalt en fantastisk historie om virkningen af Daratumumab hos en kvinde med sygdommen.
-
-
"I
n addition to the 6 patients who achieved complete responses with daratumumab, 3 patients had very good partial responses, and 7 had partial responses. Only 2 patients did not achieve an objective response to treatment with daratumumab, Kaufman reported"
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind